Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 1191-1198

  Ferraldeschi, Roberta ^a   Arnedos, Monica ^b   Hadfield, Kristen D ^a   A'Hern, Roger ^b   Drury, Suzie ^c   Wardley, Andrew ^a   Howell, Anthony ^a   Evans, D Gareth ^a   Roberts, Stephen A ^a   Smith, Ian ^b   Newman, William G ^a   Dowsett, Mitch ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breast cancer Aromatase inhibitor Polymorphism Endocrine therapy

Indexed keywords

ADENINE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; TAMOXIFEN; THYMINE;

ADJUVANT THERAPY; ADULT; AGED; ALLELE; BREAST METASTASIS; CANCER GRADING; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CYP19A1 GENE; DISEASE FREE INTERVAL; DNA EXTRACTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 84863722029     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2010-z     Document Type: Review

References (38)

1. Corbin CJ, Grahamlorence S, McPhaul M, Mason JI, Mendelson CR, Simpson ER (1988) Isolation of a full-length cDNAinert encoding human aromatase system cytochrome P-450 and its expression in nonsteroidogenic cells. Proc Natl Acad Sci USA 85(23):8948-8952
2. Smith IE, Dowsett M (2003) Drug therapy: aromatase inhibitors in breast cancer. N Engl J Med 348(24):2431-2442
3. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M, Semiglazov V, Letrozole Neo Adjuvant Breast Cancer Study Group (2001) Preoperative treatment of postmenopausal breast cancer patients with letroz-ole: a randomized double-blind multicenter study. Ann Oncol 12(11):1527-1532
4. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23(22):5108-5116. doi:10.1200/jco.2005.04.005
5. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, Investigators AL (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11(12): 1135-1141. doi:10.1016/s1470.2045(10)70257.6
6. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Lang I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25(5):486-492. doi:10.1200/jco.2006.08.8617
7. Wang LW, McLeod HL, Weinshilboum RM (2011) Genomic medicine genomics and drug response. N Engl J Med 364(12): 1144-1153
8. Ma CX, Adjei AA, Salavaggione OE, Coronel J, Pelleymounter L, Wang LW, Eckloff BW, Schaid D, Wieben ED, Weinshilboum RM (2005) Human aromatase: gene resequencing and functional genomics. Cancer Res 65(23):11071-11082. doi:10.1158/0008-5472.can-05-1218
9. Wang LW, Ellsworth KA, Moon I, Pelleymounter LL, Eckloff BW, Martin YN, Fridley BL, Jenkins GD, Batzler A, Suman VJ, Ravi S, Dixon JM, Miller WR, Wieben ED, Buzdar A, Wein-shilboum RM, Ingle JN (2010) Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 70(1):319-328. doi:10.1158/0008-5472.can-09-3224
10. Ma XY, Qi XW, Chen CH, Lin H, Xiong HY, Li YF, Jiang J (2010) Association between CYP19 polymorphisms and breast cancer risk: results from 10, 592 cases and 11, 720 controls. Breast Cancer Res Treat 122(2):495-501. doi:10.1007/s10549-009-0693-6
11. Chen C, Sakoda LC, Doherty JA, Loomis MM, Fish S, Ray RM, Lin MG, Fan WH, Zhao LP, Gao DL, Stalsberg H, Feng ZD, Thomas DB (2008) Genetic variation an CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17(12): 3457-3466. doi:10.1158/1055-9965.epi-08-0517
12. Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G, Thun MJ, Albanes D, Altshuler D, Ardanaz E, Boeing H, Buring J, Burtt N, Calle EE, Chanock S, Clavel-Chapelon F, Colditz GA, Cox DG, Feigelson HS, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Le Marchand L, Lenner P, Lund E, Panico S, Peeters PH, Pike MC, Riboli E, Tjonneland A, Travis R, Trich-opoulos D, Wacholder S, Ziegler RG (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67(5):1893-1897. doi:10.1158/0008-5472.can-06-4123
13. Cai QY, Kataoka N, Li C, Wen WQ, Smith JR, Gao YT, Shu XO, Zheng W (2008) Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 17(1):27-32. doi: 10.1158/1055-9965.epi-07-0688
14. Fasching PA, Loehberg CR, Strissel PL, Lux MP, Bani MR, Schrauder M, Geiler S, Ringleff K, Oeser S, Weihbrecht S, Schulz-Wendtland R, Hartmann A, Beckmann MW, Strick R (2008) Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. Breast Cancer Res Treat 112(1):89-98. doi:10.1007/s10549-007-9822-2
15. Huang CS, Kuo SH, Lien HC, Yang SY, You SL, Shen CY, Lin CH, Lu YS, Chang KJ (2008) The CYP19 TTTA repeat polymorphism is related to the prognosis of premenopausal stage I-II and operable stage III breast cancers. Oncologist 13(7):751-760. doi:10.1634/theoncologist.2007-0246
16. Long JR, Kataoka N, Shu XO, Wen WQ, Gao YT, Cai QY, Zheng W (2006) Genetic polymorphisms of the CYP19A1 gene and breast cancer survival. Cancer Epidemiol Biomarkers Prev 15(11):2115-2122. doi:10.1158/1055-9965.epi-06-0464
17. Dunning AM, Dowsett M, Healey CS, Tee L, Luben RN, Folkerd E, Novik KL, Kelemen L, Ogata S, Pharoah PDP, Easton DF, Day NE, Ponder BAJ (2004) Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 96(12):936-945. doi:10.1093/jnci/djh167
18. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanc-zyk FZ, McTiernan A (2004) Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 13(1):94-101
19. Lunardi G, Del Mastro L, Serra M, Driol P, Boni C, Cognetti F, Ponzone R, Porpiglia M, Venturini M, Pronzato P, Gruppo Ital-iano Mammella (Gim) (2009) Plasma levels of estrone sulfate (ES) in postmenopausal women with breast cancer (BC) during letrozole (L) treatment: association with single nucleotide polymorphisms (SNPs) of CYP19A1. J Clin Oncol 27(15):555
20. Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM, Barnadas A, Calvo L, Carabantes F, Crespo C, Munoz M, Llombart A, Plaz-aola A, Artells R, Gilabert M, Lloveras B, Alba E (2008) A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma. Clin Cancer Res 14(3):811-816. doi: 10.1158/1078-0432.ccr-07-1923
21. 0-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer. doi: 10.1186/1471-2407-10-36
22. Park IH, Ro J, Lee KS, Kim SY, Lee YS (2009) Single nucleotide polymorphisms of CYP19A1, rs10459592 and r4775936 predict clinical benefit of letrozole in patients with metastatic breast cancer. Cancer Res 69(24):630S-631S
23. Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, Demichele A (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13(1):R8 [Epub ahead of print]
24. Kadouri L, Bercovich D, Rottenberg Y, Korem S, Elimelech A, Uziely B, Safra T, Ron IG, Peretz T, Yaal-Hahoshen N (2008) Effect of single-nucleotide polymorphisms in the CYP19 gene on response to Letrozole among breast cancer patients. J Clin Oncol 22096
25. Czajka-Oraniec I, Zgliczynski W, Kurylowicz A, Mikula M, Ostrowski J (2008) Association between gynecomastia and aro-matase (CYP19) polymorphisms. Eur J Endocrinol 158(5): 721-727. doi:10.1530/eje-07-0556
26. Tsuchiya N, Wang L, Suzuki H, Segawa T, Fukuda H, Narita S, Shimbo M, Kamato T, Mitsumori K, Ichikawa T, Qgawa S, Nakamura A, Habuchi T (2006) Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer. J Clin Oncol 24(13):1982-1989. doi:10.1200/jco. 2005.02.9439
27. Gennari L, Masi L, Merlotti D, Picariello L, Falchetti A, Tanini A, Mavilia C, Del Monte F, Gonnelli S, Lucani B, Gennari C, Brandi ML (2004) A polymorphic CYP19 TTTA repeat influences aromatase activity and estrogen levels in elderly men: effects on bone metabolism. J Clin Endocrinol Metab 89(6): 2803-2810. doi:10.1210/jc.2003-031342
28. Haiman CA, Hankinson SE, Spiegelman D, De Vivo I, Colditz GA, Willett WC, Speizer FE, Hunter DJ (2000) A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer 87(2):204-210
29. Hochberg YBY (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol) 57(1):289-300
30. Payne EJ, Ingley E, Dick IM, Wilson SG, Bond CS, Prince RL (2009) In vitro kinetic properties of the Thr(201)Met variant of human aromatase gene CYP19A1: functional responses to substrate and product inhibition and enzyme inhibitors. J Clin Endocrinol Metab 94(8):2998-3002. doi:10.1210/jc.2008-2309
31. Park IH, Lee YS, Lee KS, Kim SY, Hong SH, Jeong J, Lee H, Ro J, Nam BH (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol. doi:10.1007/s00280-011-1615-y
32. Enjuanes A, Garcia-Giralt N, Supervia A, Nogues X, Ruiz-Gaspa S, Bustamante M, Mellibovsky L, Grinberg D, Balcells S, Diez-Perez A (2006) A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone 38(5):738-743. doi:10.1016/j. bone.2005.10.010
33. Berstein LM, Imyanitov EN, Suspitsin EN, Grigoriev MY, Sokolov EP, Togo A, Hanson KP, Poroshina TE, Vasiljev DA, Kovalevskij AY, Gamajunova VB (2001) CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 127(2):135-138
34. Travis RC, Churchman M, Edwards SA, Smith G, Verkasalo PK, Wolf CR, Wolf H, Key TJ (2004) No association of polymorphisms in CYP17, CYP19, and HSD17-B1 with plasma estradiol concentrations in 1, 090 British women. Cancer Epidemiol Bio-markers Prev 13(12):2282-2284
35. Thompson AM, Johnson A, Quinlan P, Hillman G, Fontecha M, Bray SE, Purdie CA, Jordan LB, Ferraldeschi R, Latif A, Had-field KD, Clarke RB, Ashcroft L, Evans DG, Howell A, Nikoloff M, Lawrence J, Newman WG (2011) Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Res Treat 125(1):279-287. doi:10.1007/s10549-010-1139-x
36. Janni W, Hepp P (2010) Adjuvant aromatase inhibitor therapy: outcomes and safety. Cancer Treat Rev 36(3):249-261. doi: 10.1016/j.ctrv.2009.12.010
37. Ingle JN, Schaid DJ, Goss PE, Liu M, Mushiroda T, Chapman JAW, Kubo M, Jenkins GD, Batzler A, Shepherd L, Pater J, Wang LW, Ellis MJ, Stearns V, Rohrer DC, Goetz MP, Pritchard KI, Flockhart DA, Nakamura Y, Weinshilboum RM (2010) Genome-wide associations and functional genomic studies of musculo-skeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28(31):4674-4682. doi:10.1200/jco.2010.28.5064
38. Setiawan VW, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I (2004) HSD17B1 gene polymorphisms and risk of endometrial and breast cancer. Cancer Epidemiol Biomarkers Prev 13(2): 213-219